Is acalatinib/acalabrutinib suitable for long-term use?

Acalabrutinib, also known as acalabrutinib, is now approved as an effective treatment for lymphoma, specifically mantle cell lymphoma (MCL). Long-term study data shows the drug demonstrated durable efficacy in treatment-naïve patients with chronic lymphocytic leukemia (CLL). Subsequently, the study was further expanded, and the drug was also approved for treatment of first-time treatment patients with relapsed or refractory CLL and patients with small lymphocytic lymphoma.

As a second-generation selective BTK inhibitorAcotinib has shown lower off-target activity in non-clinical studies than first-generation BTK inhibitors such as ibrutinib, and its single-agent treatment regimen has also produced significant and durable responses. Acotinib is designed as a long-term treatment regimen, and each dose is a testimony of the patient's fight against the disease. Although discontinuing acotinib therapy may seem an attractive option when a patient's blood cell counts return to the normal range, patients are strongly advised not to discontinue treatment without clear guidance from their physician. During the entire treatment process, patients should strictly abide by the doctor's medication instructions.

If any side effects occur while taking the medication, the doctor may adjust the dose based on the patient's specific condition or recommend temporarily or permanently discontinuing the medication. The standard dosing schedule for acotinib is twice a day, with a dosing interval of approximately 12 hours. Patients should swallow the tablets whole with a glass of water and avoid chewing, crushing, dissolving, or cutting the tablets. If you miss a dose of medication, take it as soon as you remember. However, if it has been more than 3 hours since your regular dose, skip the missed dose and take the next dose at the originally scheduled time. It is important that patients should not increase their dose to compensate for missed doses.